Zydus Lifesciences Gets USFDA Nod for Generic Schizophrenia Drug
By Rediff Money Desk, New Delhi Oct 10, 2024 15:44
Zydus Lifesciences has received USFDA approval to manufacture generic Paliperidone extended-release tablets, used to treat schizophrenia. The tablets will be produced at the company's Ahmedabad facility.
New Delhi, Oct 10 (PTI) Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture its generic version of Paliperidone extended-release tablets, used to treat schizophrenia.
The approval by the US Food and Drug Administration (USFDA) is for Paliperidone extended-release tablets of strengths 1.5 mg, 3 mg, 6 mg, and 9 mg, Zydus Lifesciences said in a regulatory filing.
These tablets will be produced at the group's manufacturing site at SEZ, Ahmedabad, it added.
Paliperidone extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia, acute treatment of schizoaffective disorder as monotherapy and acute treatment of schizoaffective disorder as an adjunct to mood stabilisers and/or antidepressants, the company said.
The approval by the US Food and Drug Administration (USFDA) is for Paliperidone extended-release tablets of strengths 1.5 mg, 3 mg, 6 mg, and 9 mg, Zydus Lifesciences said in a regulatory filing.
These tablets will be produced at the group's manufacturing site at SEZ, Ahmedabad, it added.
Paliperidone extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia, acute treatment of schizoaffective disorder as monotherapy and acute treatment of schizoaffective disorder as an adjunct to mood stabilisers and/or antidepressants, the company said.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Srestha Finvest
- 0.89 (+ 4.71)
- 84074150
- Jaiprakash Power Ven
- 22.89 (+ 3.34)
- 47620916
- Spicejet Ltd.
- 65.25 ( -0.78)
- 27318841
- AvanceTechnologies
- 0.90 (+ 4.65)
- 26883863
- Vodafone Idea L
- 9.32 (+ 1.41)
- 26185410
MORE NEWS
Ireda Q2 Profit Surges 36% to Rs 388 cr |...
State-owned Ireda's net profit jumped 36% to Rs 388 crore in Q2 FY24, driven by higher...
Social Security Benefits to Rise 2.5% in 2025
Social Security recipients will receive a 2.5% cost-of-living adjustment in 2025,...
Mumbai Property Registrations Rise 7% in...
Property registrations in Mumbai Metropolitan Region (MMR) rose 7% in Jul-Sep, driven...